Mission statement · Company scope
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”
In use2026 – now1 sighting
First seenFeb 2026Added
Last seenFeb 2026Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Innovation (primary) · Market leadership · Customer-centric
- Leads with
- Invention
- Best for
- Climate & health
- Formula
- We’re building [new thing] so [result]
- Tone
- Plain
- Length
- 26 words · reading grade 17.2
- Review status
- unreviewed · classifier rules-v0
- Quality score
- 0.74
- Record
- st_cb6040be0eac48db
- Classification confidence
- 0.59
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2026-02-24 · sec_sentence · 10-K · accession 0001104659-26-018899
View filing ↗0 to compareCompare